JUN 09, 2016 2:52 PM PDT

Making Bone Marrow Transplants Safer with Antibodies

WRITTEN BY: Xuan Pham

For some patients, bone marrow transplants are one of the few last defenses that could save their lives. But this procedure is extremely dangerous and prone to side-effects that could last a lifetime. Now researchers at the Harvard Medical School have developed a new way to transplant bone marrow that’s safer and more effective. Their work, though only done in mice, give hope that the technology could one day be applied safely to millions of people who are in desperate need of the life-saving procedure.

David Scadden and Rahul PalchaudhuriA bone marrow transplant is a procedure that replaces a patient’s diseased blood stem cells with healthy ones from a matched donor. There are several conditions that warrant a bone marrow transplant. These often involve blood disorders, such as cancer of the blood (leukemia), sickle cell anemia, or thalassemia. In some instances, chemotherapy or radiation treatment can damage the bone marrow, necessitating a transplant.

Before doctors can transplant healthy donor cells into a recipient patient, they must first wipe out the diseased blood cells from the patient’s bone marrow. This requires extremely toxic treatments that increase the risk for complications such as bleeding, infection, and organ damage. As such, finding a safer way to deliver this procedure is critical.

In order to get rid of diseased blood cells safely, researchers at Harvard turned to antibodies, which are inherently specific to their targets. "Instead of using non-targeted drugs that have lots of collateral damage we thought we could take advantage of the precision of the immune system, in particular, antibodies," said David Scadden, Professor of Medicine at Harvard University, and senior study author.

The team armed antibodies with a killing payload that’s specific to a blood marker known as CD45. "Antibodies are remarkably specific in what they target," said Rahul Palchaudhuri, the study’s first author. "We can direct them to CD45, a cell marker which is exclusively expressed in the blood system. That way we avoid toxicities to non-blood tissues."
 

 


In this approach, the antibodies can’t harm the thymus and bone marrow environments, which are crucial nurseries for T cells and innate immune cells. As a result, the body can still defend itself against infections that would otherwise be dangerously fatal if these cells were destroyed.

They tested their procedure in mice, and showed that mice with antibody treatment withstood infection better than mice treated with standard radiation. Antibody treatment also enabled mice to accept a bone marrow transplant, and be cured of their sickle cell anemia condition.

Interestingly, the team reported no severe adverse effects in mice given the antibody treatment, even if transplants didn’t follow. This means that the procedure won’t confine patients to a long, sterile hospital bed while they recover, and that a failed transplant won’t be fatal. But the caveat is that these results have only been observed in animal studies.

"If this approach works in humans, it will really change the conversation that providers have with patients," Scadden said. The procedure would open transplant possibilities especially for those "who have these underlying genetic disorders and for who the new gene-editing and gene therapy techniques are being developed."

Additional sources: Science Daily

Image credit: BD Bolen & Harvard Medical School

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 07, 2020
Clinical & Molecular DX
JAN 07, 2020
Kiss and tell: new test for kissing bug disease
Here’s one Latin lover that you do not want to get kissed by: triatomines, or “kissing bugs”. Known lo ...
FEB 10, 2020
Microbiology
FEB 10, 2020
As Ebola Outbreak Continues, Researchers Create Faster Genetic Test
Since 2013, around 30,000 people have been infected during several outbreaks of Ebola in eight different countries.
MAR 05, 2020
Drug Discovery & Development
MAR 05, 2020
Human Stem Cells Cure Type 1 Diabetes in Mice
In the US alone, around 187,000 children and adolescents have Type 1 diabetes, alongside 1.4 million people aged 20 and ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 22, 2020
Clinical & Molecular DX
APR 22, 2020
Microneedle Skin Patch Collects Bodily Fluids for On-patch Diagnostic Testing
The collection of blood for diagnostic tests is common practice in clinical settings. However, technicians often need to ...
MAY 23, 2020
Microbiology
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
Loading Comments...